Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
作者信息
Kremens Daniel, Lew Mark, Claassen Daniel, Goodman Brent P
机构信息
Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
Department of Neurology, University of Southern California, Los Angeles, CA, USA.
出版信息
Clin Auton Res. 2017 Jul;27(Suppl 1):29-31. doi: 10.1007/s10286-017-0434-6. Epub 2017 Jul 3.
Abstract
摘要
相似文献
1
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.在患有神经源性直立性低血压和帕金森病的患者中，将屈昔多巴添加到氟氢可的松或米多君中。
Clin Auton Res. 2017 Jul;27(Suppl 1):29-31. doi: 10.1007/s10286-017-0434-6. Epub 2017 Jul 3.
2
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.调整屈昔多巴治疗帕金森病患者神经源性直立性低血压
Clin Auton Res. 2017 Jul;27(Suppl 1):17-19. doi: 10.1007/s10286-017-0431-9. Epub 2017 Jun 19.
3
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.多重用药：使用屈昔多巴治疗一名帕金森病合并2型糖尿病患者的神经源性直立性低血压。
Clin Auton Res. 2017 Jul;27(Suppl 1):33-34. doi: 10.1007/s10286-017-0435-5. Epub 2017 Jul 3.
4
Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.在患有神经源性直立性低血压的成年人中，与米多君相比，屈昔多巴对站立血压和直立耐受性的有效性：一项系统评价方案
JBI Database System Rev Implement Rep. 2017 Sep;15(9):2287-2294. doi: 10.11124/JBISRIR-2016-003306.
5
Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.在一名多系统萎缩患者中定义用屈昔多巴成功治疗神经源性直立性低血压。
Clin Auton Res. 2017 Jul;27(Suppl 1):21-23. doi: 10.1007/s10286-017-0432-8. Epub 2017 Jun 19.
6
Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.在一名帕金森病患者中启动屈昔多巴治疗神经源性直立性低血压。
Clin Auton Res. 2017 Jul;27(Suppl 1):13-14. doi: 10.1007/s10286-017-0429-3. Epub 2017 Jun 19.
7
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.滴定屈昔多巴以最大化帕金森病合并神经源性直立性低血压患者的症状获益。
Clin Auton Res. 2017 Jul;27(Suppl 1):15-16. doi: 10.1007/s10286-017-0430-x. Epub 2017 Jul 11.
8
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.体位性低血压患者使用屈昔多巴和米多君的立位和卧位血压结局：随机试验的贝叶斯荟萃分析和混合治疗比较。
Ann Pharmacother. 2018 Dec;52(12):1182-1194. doi: 10.1177/1060028018786954. Epub 2018 Jul 4.
9
Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.在一名患有帕金森病、心房颤动和高血压的患者中使用屈昔多巴治疗神经源性直立性低血压
Clin Auton Res. 2017 Jul;27(Suppl 1):25-27. doi: 10.1007/s10286-017-0433-7. Epub 2017 Jun 20.
10
Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.帕金森病患者疑似神经源性直立性低血压的鉴别诊断。
Clin Auton Res. 2017 Jul;27(Suppl 1):5-7. doi: 10.1007/s10286-017-0427-5. Epub 2017 Jul 3.
引用本文的文献
1
Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies.神经源性直立性低血压：现状与治疗策略
Clin Med Insights Cardiol. 2020 Aug 30;14:1179546820953415. doi: 10.1177/1179546820953415. eCollection 2020.
2
Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.神经原性直立性低血压的临床试验：终点、陷阱和挑战的综合评价。
Semin Neurol. 2020 Oct;40(5):523-539. doi: 10.1055/s-0040-1713846. Epub 2020 Sep 9.
3
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.多佐胺治疗淀粉样变轻链淀粉样变性致难治性神经源性直立性低血压和反射性心动过缓：1 例报告。
J Med Case Rep. 2020 Jun 20;14(1):73. doi: 10.1186/s13256-020-02405-w.
4
Orthostatic Hypotension in Parkinson Disease.帕金森病患者的直立性低血压。
Clin Geriatr Med. 2020 Feb;36(1):53-67. doi: 10.1016/j.cger.2019.09.002. Epub 2019 Sep 6.
5
Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.遗传性转甲状腺素蛋白淀粉样变性的直立性低血压：流行病学、诊断和治疗。
Clin Auton Res. 2019 Sep;29(Suppl 1):33-44. doi: 10.1007/s10286-019-00623-x. Epub 2019 Aug 26.
6
A Stage-Based Approach to Therapy in Parkinson's Disease.帕金森病的阶段治疗方法。
Biomolecules. 2019 Aug 20;9(8):388. doi: 10.3390/biom9080388.
7
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.帕金森病和其他突触核蛋白病自主神经功能障碍的治疗。
Mov Disord. 2018 Mar;33(3):372-390. doi: 10.1002/mds.27344.
本文引用的文献
1
Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study.盐酸米多君对症状性直立性低血压的临床疗效：一项4期、双盲、安慰剂对照、随机倾斜试验研究
Clin Auton Res. 2016 Aug;26(4):269-77. doi: 10.1007/s10286-016-0363-9. Epub 2016 Jul 2.
2
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.多巴丝肼治疗神经源性直立性低血压的安全性和有效性的荟萃分析。
Clin Auton Res. 2016 Jun;26(3):171-80. doi: 10.1007/s10286-016-0349-7. Epub 2016 Mar 7.
3
Supine hypertension in Parkinson's disease and multiple system atrophy.帕金森病和多系统萎缩中的仰卧位高血压
Clin Auton Res. 2016 Apr;26(2):97-105. doi: 10.1007/s10286-015-0336-4. Epub 2016 Jan 22.
4
Clinical characteristics of supine hypertension in de novo Parkinson disease.新发帕金森病患者仰卧位高血压的临床特征。
Clin Auton Res. 2016 Feb;26(1):15-21. doi: 10.1007/s10286-015-0324-8. Epub 2015 Nov 27.
5
Droxidopa in neurogenic orthostatic hypotension.屈昔多巴治疗神经源性直立性低血压。
Expert Rev Cardiovasc Ther. 2015;13(8):875-91. doi: 10.1586/14779072.2015.1057504. Epub 2015 Jun 19.
6
Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).屈昔多巴用于帕金森病症状性神经源性直立性低血压的短期治疗（nOH306B）
Mov Disord. 2015 Apr 15;30(5):646-54. doi: 10.1002/mds.26086. Epub 2014 Dec 9.
Zotero 插件